FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4318578719> ?p ?o ?g. }

• W4318578719 endingPage "i775" @default.
• W4318578719 startingPage "i774" @default.
• W4318578719 abstract "Abstract Background Some patients with Inflammatory Bowel Disease (IBD) who are treated with anti-TNFα therapy develop a drug-induced psoriasis (IP) as an adverse event. There are some therapeutic approaches, being more frequent to change the biologic therapy to ustekinumab, effective and approved for the treatment of both entities. This could be the best option, but available data are lacking and it could increase the risk of IBD relapse. Our aim is to assess the management of anti-TNF IP in IBD, and the subsequent evolution of both diseases in a large nationwide cohort of patients. Methods Retrospective, observational multicenter study from the prospectively maintained Spanish ENEIDA registry. Participants were patients with IBD and anti-TNFα IP. At baseline, psoriasis severity was classified as mild, moderate or severe, and remission was defined as the resolution of skin lesions, clinical response as an improvement without complete resolution, and no response as the absence of improvement. IBD clinical activity was defined based on Harvey-Bradshaw Index and Partial Mayo Score. All items were evaluated when available at baseline and 16, 32 and 54 weeks. Results Anti-TNFα IP was reported in 234 patients (CD: 185, UC: 46, unclassified IBD: 3). SWAP strategy was chosen in 76 patients (32.5%), most of them to ustekinumab (90.8%), 71 (30.3%) patients continued anti-TNF, 49 (20.9%) discontinued it, and in 38 (16.2%) a switch to a second anti-TNF was made. The decision to continue or not anti-TNF was associated to psoriasis severity (p&lt;0.001) and baseline IBD activity (p=0.03). In mild psoriasis, anti-TNF was continued in 56.81% of patients, whereas SWAP and withdrawal of the anti-TNF were the most used in moderate and severe disease (32.3% and 36.5% respectively). SWAP strategy was also the most used in active IBD (46%). During follow-up, CD activity got worse in anti-TNF withdrawal group (p=0.003), without differences in the other groups. Regarding to psoriatic lesions, all strategies showed a significant improvement, with worse results when anti-TNF was continued (remission rate of 58%, p=0.042), and without differences between the other strategies at week 54. In multivariate analysis, male gender was associated with IBD remission (HR 0.233; IC95% 0.061-0.894). Trunk (OR 2.777; IC95% 1.120-6.889), as well as palms and soles location (OR 2.091; IC95% 1.018-4.294), and stopping anti-TNF treatment (OR 3.010; IC95% 1.110-8.159), were independently associated with remission of skin lesions. Conclusion Evaluating IBD activity and psoriasis severity is essential before modifying IBD treatment due to IP. Continuing anti-TNF treatment in mild psoriasis cases, and considering SWAP to ustekinumab in moderate-severe ones, could be a suitable strategy." @default.
• W4318578719 created "2023-01-31" @default.
• W4318578719 creator A5000562606 @default.
• W4318578719 creator A5003918175 @default.
• W4318578719 creator A5008020027 @default.
• W4318578719 creator A5009906875 @default.
• W4318578719 creator A5010338040 @default.
• W4318578719 creator A5011716973 @default.
• W4318578719 creator A5011756766 @default.
• W4318578719 creator A5012338853 @default.
• W4318578719 creator A5014193387 @default.
• W4318578719 creator A5014945298 @default.
• W4318578719 creator A5017557984 @default.
• W4318578719 creator A5018028724 @default.
• W4318578719 creator A5021002325 @default.
• W4318578719 creator A5024930111 @default.
• W4318578719 creator A5026305732 @default.
• W4318578719 creator A5027193155 @default.
• W4318578719 creator A5035612281 @default.
• W4318578719 creator A5036181122 @default.
• W4318578719 creator A5036318695 @default.
• W4318578719 creator A5038357182 @default.
• W4318578719 creator A5039119396 @default.
• W4318578719 creator A5040944358 @default.
• W4318578719 creator A5042665707 @default.
• W4318578719 creator A5042827079 @default.
• W4318578719 creator A5044318805 @default.
• W4318578719 creator A5048489661 @default.
• W4318578719 creator A5051263331 @default.
• W4318578719 creator A5056364928 @default.
• W4318578719 creator A5058402704 @default.
• W4318578719 creator A5059193792 @default.
• W4318578719 creator A5059228647 @default.
• W4318578719 creator A5059680308 @default.
• W4318578719 creator A5064167457 @default.
• W4318578719 creator A5068681098 @default.
• W4318578719 creator A5070845683 @default.
• W4318578719 creator A5076400447 @default.
• W4318578719 creator A5078866325 @default.
• W4318578719 creator A5079935064 @default.
• W4318578719 creator A5087554856 @default.
• W4318578719 creator A5087857124 @default.
• W4318578719 date "2023-01-30" @default.
• W4318578719 modified "2023-10-17" @default.
• W4318578719 title "P643 Psoriasis induced by anti-TNF therapy in Inflammatory Bowel Disease: analysis of therapeutic management and evolution of both diseases in a nationwide cohort study" @default.
• W4318578719 doi "https://doi.org/10.1093/ecco-jcc/jjac190.0773" @default.
• W4318578719 hasPublicationYear "2023" @default.
• W4318578719 type Work @default.
• W4318578719 citedByCount "0" @default.
• W4318578719 crossrefType "journal-article" @default.
• W4318578719 hasAuthorship W4318578719A5000562606 @default.
• W4318578719 hasAuthorship W4318578719A5003918175 @default.
• W4318578719 hasAuthorship W4318578719A5008020027 @default.
• W4318578719 hasAuthorship W4318578719A5009906875 @default.
• W4318578719 hasAuthorship W4318578719A5010338040 @default.
• W4318578719 hasAuthorship W4318578719A5011716973 @default.
• W4318578719 hasAuthorship W4318578719A5011756766 @default.
• W4318578719 hasAuthorship W4318578719A5012338853 @default.
• W4318578719 hasAuthorship W4318578719A5014193387 @default.
• W4318578719 hasAuthorship W4318578719A5014945298 @default.
• W4318578719 hasAuthorship W4318578719A5017557984 @default.
• W4318578719 hasAuthorship W4318578719A5018028724 @default.
• W4318578719 hasAuthorship W4318578719A5021002325 @default.
• W4318578719 hasAuthorship W4318578719A5024930111 @default.
• W4318578719 hasAuthorship W4318578719A5026305732 @default.
• W4318578719 hasAuthorship W4318578719A5027193155 @default.
• W4318578719 hasAuthorship W4318578719A5035612281 @default.
• W4318578719 hasAuthorship W4318578719A5036181122 @default.
• W4318578719 hasAuthorship W4318578719A5036318695 @default.
• W4318578719 hasAuthorship W4318578719A5038357182 @default.
• W4318578719 hasAuthorship W4318578719A5039119396 @default.
• W4318578719 hasAuthorship W4318578719A5040944358 @default.
• W4318578719 hasAuthorship W4318578719A5042665707 @default.
• W4318578719 hasAuthorship W4318578719A5042827079 @default.
• W4318578719 hasAuthorship W4318578719A5044318805 @default.
• W4318578719 hasAuthorship W4318578719A5048489661 @default.
• W4318578719 hasAuthorship W4318578719A5051263331 @default.
• W4318578719 hasAuthorship W4318578719A5056364928 @default.
• W4318578719 hasAuthorship W4318578719A5058402704 @default.
• W4318578719 hasAuthorship W4318578719A5059193792 @default.
• W4318578719 hasAuthorship W4318578719A5059228647 @default.
• W4318578719 hasAuthorship W4318578719A5059680308 @default.
• W4318578719 hasAuthorship W4318578719A5064167457 @default.
• W4318578719 hasAuthorship W4318578719A5068681098 @default.
• W4318578719 hasAuthorship W4318578719A5070845683 @default.
• W4318578719 hasAuthorship W4318578719A5076400447 @default.
• W4318578719 hasAuthorship W4318578719A5078866325 @default.
• W4318578719 hasAuthorship W4318578719A5079935064 @default.
• W4318578719 hasAuthorship W4318578719A5087554856 @default.
• W4318578719 hasAuthorship W4318578719A5087857124 @default.
• W4318578719 hasBestOaLocation W43185787191 @default.
• W4318578719 hasConcept C126322002 @default.
• W4318578719 hasConcept C167135981 @default.
• W4318578719 hasConcept C197934379 @default.
• W4318578719 hasConcept C201903717 @default.
• W4318578719 hasConcept C203014093 @default.
• W4318578719 hasConcept C23131810 @default.
• W4318578719 hasConcept C2777011040 @default.

• next